Table 5. The league table for SAE estimates interventions according to their relative effects in first part network analysis.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Apatoren+Taxane (49.6%)# |  |  |  |  |  |  |
| -0.21 (-2.02,1.61) | Icrucumab+Taxane (38.5%) |  |  |  |  |  |
| -0.25 (-2.00,1.51) | -0.04 (-1.85,1.77) | Pazopanib (36.7%) |  |  |  |  |
| 0.18 (-1.36,1.73) | 0.39 (-0.98,1.76) | 0.43 (-1.11,1.97) | Ramucirumab+Taxane (59.7%) |  |  |  |
| 0.47 (-0.77,1.71) | 0.68 (-0.64,2.00) | 0.72 (-0.52,1.96) | 0.29 (-0.63,1.21) | Taxane (79.8%) |  |  |
| -0.50 (-2.25,1.24) | -0.29 (-2.10,1.51) | -0.26 (-2.00,1.49) | -0.69 (-2.22,0.85) | -0.98 (-2.20,0.25) | Vandetanib+Taxane (24.7%) |  |
| 0.24 (-1.62,2.11) | 0.45 (-1.47,2.37) | 0.49 (-1.37,2.35) | 0.06 (-1.61,1.73) | -0.23 (-1.62,1.16) | 0.75 (-1.11,2.60) | Vinflunine (61.1%) |

#: The SUCRA probabilities are performed in brackets.

Abbreviations: SAE: Severe adverse effect.